Member Info for mazik

Weak are being shaken out and investors are taking advantage of the weakness imo...expect blue at close...

With due respect Chartist's assumption is correct on large shareholder's holdings ie Farrier and institutional holding.
While the weak holders wither away some holders await anxiously of a successful Q4 result, my taking is that the last 3 RNS speaks for itself , now this investment is for the brave.

Charty a positive update on Nuvec could take us back to mcap to £20m .Imo

On the 12th we had code 1 on the buy column today code 1 on the sell column....so it means sod all to me....

Good morning John u said its Barclay's Nominee's account within individual ISA and dealing accounts.

Well a great investment here Koov is open to a billion let alone in India, rest of Asia can be put to your imagination.imo

Interesting Vander

Thank u Vander for sharing your research.

Thanks Tom

I am in first time in koovs based on its format like Amazon and the market they will exploit..25k shares as a starter..have not done much research here..

Options were set at 6.60, keeping that as a base had been oversold with the market.There is no logic but its nice to see a bit of blue as we move north.imo

Mancave I feel we are well oversold since the spike of 21st. all the T trades have been settled, now I suspect peeps are anticipating positive news of the Medimmune collaboration. IMO well for all I have my fingers crossed :-)

Expected Med news with the Q4 news by November..imo

Good morning Bob, at normal times it would have been a good idea to have an xmas draw since most of us are down over 75% plus thought its better to be quite and let the news update do the talking. At best lets keep the trolls out :-) GLA.

Applegarth I know someone has been abusing your alias for the last 6 months, thank u for your understanding :-)

Do we need this crap on this thread?

The pre-clinical milestone for NXP001 has been achieved, triggering a payment of an initial £500,000 to the Company.
In line with the agreement with NSB for NXP001, the demonstration of human bioequivalence to the reference product will trigger a further £2 million payment from NSB, which under the agreement has exclusive rights to NXP001 for marketing and distribution in China. Nuformix is in discussions with multiple parties regarding the marketing of the Rest of World rights for NXP001. Sure we can afford to hire a broker :-)

Hi Petty, we seem to be doing everything expect not got a broker since march as they announced they were looking for a replacement of BS of their last demised broker. Does it take that long? I thought some would be head over heals to satisfy this opportunity. I am a holder since last year, could someone update me on this, as I am truly lost :-)

https://www.proactiveinvestors.co.uk/companies/news/205525/n4-pharmas-nuvec-delivery-system-gets-free-shot-in-arm-205525.htm
( Sorry guys if this has already been put up here to share) :-)

Applegarth same here been averaging since the drop of 9th july, since then all positive news on nuvec .Having accepted the closing of reformulation to concentrate on nuvec that it makes business sense with the collaboration with med i believe the closing date is 18th which is tomorrow then i expect an update after 2 weeks. Rest i wish all involved all the success the managment and the investors.